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Economic evaluations provide information to aid the optimal utilization of limited healthcare
resources. Costs of biologics for Rheumatoid arthritis (RA) are remarkably high, which
makes these agents an important target for economic evaluations. This systematic review
aims to identify existing studies examining the cost-effectiveness of biologics for RA, assess
their quality and report their results systematically.
Methods
A literature search covering Medline, Scopus, Cochrane library, ACP Journal club and Web
of Science was performed in March 2013. The cost-utility analyses (CUAs) of one or more
available biological drugs for the treatment of RA in adults were included. Two independent
investigators systematically collected information and assessed the quality of the studies.
To enable the comparison of the results, all costs were converted to 2013 euro.
Results
Of the 4890 references found in the literature search, 41 CUAs were included in the current
systematic review. While considering only direct costs, the incremental cost-effectiveness
ratio (ICER) of the tumor necrosis factor inhibitors (TNFi) ranged from 39,000 to 1 273,000
€/quality adjusted life year (QALY) gained in comparison to conventional disease-modifying
antirheumatic drugs (cDMARDs) in cDMARD naïve patients. Among patients with an insuffi-
cient response to cDMARDs, biologics were associated with ICERs ranging from 12,000 to
708,000 €/QALY. Rituximab was found to be the most cost-effective alternative compared
to other biologics among the patients with an insufficient response to TNFi.
Conclusions
When 35,000 €/QALY is considered as a threshold for the ICER, TNFis do not seem to be
cost-effective among cDMARD naïve patients and patients with an insufficient response to
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cDMARDs. With thresholds of 50,000 to 100,000 €/QALY biologics might be cost-effective
among patients with an inadequate response to cDMARDs. Standardization of multiattri-
bute utility instruments and a validated standard conversion method for missing utility mea-
sures would enable better comparison between CUAs.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease with the prevalence of 0.2–1%
among adult population in Europe and North-America [1]. RA affects physical health causing
pain, stiffness, progressive joint destruction and physical disability. Medical treatment, joint
replacement surgery and productivity losses due to sick leave and early retirements lead to
significant expenses for society [2]. The treatment target of RA is remission or low disease ac-
tivity and the medication initially comprises conventional disease-modifying antirheumatic
drugs (cDMARDs) such as methotrexate (MTX), sulphasalazine (SSZ), hydroxychloroquine
(HCQ) and leflunomide (LEF), low-dose prednisolone and their combinations [3]. However,
not all patients achieve remission or low disease activity with cDMARDs due to intolerance
or lack of effectiveness. Biologic disease-modifying antirheumatic drugs (bDMARDs), also
known as biologics, cover TNF inhibitors (TNFi) (adalimumab (ADA) (Humira, AbbVie
Ltd.), certolizumab pegol (CER) (Cimzia, UCB Pharma SA), etanercept (ETN) (Enbrel, Pfizer
Ltd.), golimumab (GOL) (Simponi, Janssen Biologics B.V), infliximab (IFX) (Remicade, Jans-
sen Biologics B.V.)) and agents based on other mechanisms of action (abatacept (ABT)
(Orencia, Bristol-Myers Squibb Pharma EEIG), anakinra (ANA) (Kineret, Biovitrum AB),
rituximab (RTX) (MabThera, Roche Registration Ltd) and tocilizumab (TOC) (RoActemra,
Roche Registration Ltd.)). Biologics have proven to be an effective treatment for RA, but be-
cause of the high price, they are recommended only for patients with insufficient response or
intolerance to cDMARDs [3–6].
Economic evaluations provide information on the benefits and costs of these expensive
treatments to aid the optimal utilization of limited healthcare resources [7]. Cost-effectiveness
analysis (CEA) is the most typical form of economic evaluation for health care interventions.
In CEA, costs and effectiveness of two or more treatments are compared. The costs are mea-
sured in monetary units and effectiveness in natural units, for example in life years or pain free
days. Cost-utility analysis (CUA) is a subtype of CEA, applying quality adjusted life years
(QALY) as a measure of effectiveness. The primary outcome measure in CUAs is incremental
cost-effectiveness ratio ICER, which describes the ratio of the additional costs of a treatment
(compared to an alternative) to QALYs gained. An ICER is not reported if one treatment is
both cheaper and more effective than another, e.g. if it is dominant.
Biologics for RA are an important target for economic evaluations because of the associated
high costs. Previous systematic reviews suggest that biologics might be cost-effective at the will-
ingness to pay (WTP) threshold of 50,000–100,000 $/QALY among patients with insufficient
treatment response to cDMARD but not in cDMARD naïve patients [8–10]. However, these
reviews involve some weaknesses such as lack of quality assessment [9], insufficient reporting
of study characteristics [8] or omission of between-biologics comparison [10]. The aim of our
systematic review is to identify all existing studies examining the cost-utility of one or more bi-
ologics for RA in adults, assess their quality and report their results systematically.
The Cost-Effectiveness of Biologics for RA: A Systematic Review
PLOSONE | DOI:10.1371/journal.pone.0119683 March 17, 2015 2 / 27
Pfizer (research funding), YTK: Principal Investigator
on National register for Biologics in Finland (ROB-
FIN). ROB-FIN has received funding from AbbVie,
BMS, MSD, Roche, Pfizer and USB. JTJ, SH, MB:
authors have declared that no competing interests
exist. This does not alter the authors' adherence to
PLOS ONE policies on sharing data and materials.
Methods
Literature search
We performed a literature search aiming to identify existing CUAs assessing the cost-effective-
ness of biologics for treatment of RA. The search covering Medline, SCOPUS (including
EMBase), Cochrane library (Database of Abstracts of Reviews of Effects, Health Technology
Assessment Database, Cochrane Database of Systematic Reviews, NHS Economic Evaluation
Database, Cochrane Central Register of Controlled Trials and Cochrane Methodology Regis-
ter), ACP Journal club andWeb of science was executed in March 2013 using a search strategy
developed with a librarian. The search strategy included terms describing study design (CUA),
intervention (Biologics) and patients (RA) in different spellings. The complete search strategy
for PubMed is presented in S1 File.
No time or language restrictions were made to the literature search. The number of non-
English publications was used to investigate the existence of a language bias and publication
bias was assessed based on the number of conference abstract published as full-text.
Study selection
All references identified by the literature search were imported to reference management soft-
ware (Refworks), where duplicate records were removed. Of the remaining references, the
CUAs of one or more currently available biologics for the treatment of RA in adults were select-
ed using a pre-defined inclusion and exclusion criteria (S1 Table). The evaluation for inclusion
was conducted independently by two persons (JJ and KA) at first by titles and afterwards by
full-text. In case of disagreement, a third opinion (MB) was requested. Studies without active
comparison treatment (cDMARDs or other biologics) or QALYs as measure of effectiveness
were excluded from this systematic review. Reporting of ICER was required, if applicable. Stud-
ies published only as conference abstracts and articles without English full-text were excluded.
Data collection
The Data on patients, interventions, controls, study design (country, perspective, time horizon,
the year of resource utilization, included costs, discount rate, the source of effectiveness, the in-
strument for utility measures, study funding) and outcomes were extracted using a Microsoft
Excel—based collection form. Two assessors (JJ and SH) independently extracted the data and
discrepancies were resolved by consulting the third investigator (MB). Due to limited time and
resources, authors were not contacted for complementary information.
Quality assessment
As currently recommended, the quality of economic evaluations included was assessed using
the British Medical Journal (BMJ) checklist and in addition, the Philips`checklist for modelling
studies [11–13]. Two investigators (JJ and SH) assessed the quality of the studies independently
and the third investigator (MB) was consulted when necessary. BMJ checklist involves 35 items
and Philips’ checklist 57 items. Quality scores based on fulfilment of items and average per-
centages of the applicable criteria met were calculated. To assess the relative quality of the stud-
ies we divided studies in three categories (good, adequate and poor quality) ranking them by
using the average percentages.
Representation of results
The quantitative synthesis of the results of the studies included is not possible owing to hetero-
geneous study designs. Results of the CUAs included were stratified into five subgroups by
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type of drug used, previous treatments and response to them, and the comparator treatment as
follows: 1) Biologics for cDMARDs naive patients, 2) Biologics compared with cDMARD in
patients with an inadequate response to one or several cDMARDs, 3) Biologics compared with
other biologics among patients with an inadequate response to cDMARDs, 4) Biologics com-
pared with cDMARDs among patients with an inadequate response to TNFi(s) and 5) Biolog-
ics compared with other biologics among patients with an inadequate response to TNFi(s).
Further, CUAs were stratified according to adequateness of the comparator treatment. Ade-
quate comparator was defined as a cDMARD not used before [3].
To enable a comparison of the results, all of the reported costs were converted to euro using
the European Central Bank exchange rates (http://sdw.ecb.europa.eu) and adjusted to the price
level of the year 2013 using the price index of Health care expenditure in Finland (Statistics
Finland). ICERs including only direct costs were considered primary results due to differences
in the ways indirect costs (e.g. productivity losses) were calculated in studies. In addition,
ICERs including both direct and indirect costs were presented as secondary outcomes, if re-
ported in the original studies.
Results
Altogether, 4653 non-duplicate references were identified with the literature search, of which
3113 were excluded during title and abstract screening (Fig. 1). After the assessment of 237
full-text articles, 41 were included in the current review. A majority of the studies excluded by
full-text assessment did not meet the inclusion criteria (105 studies) or were published only as
conference abstracts (71 studies). The list of the articles excluded after full-text assessment is
displayed in S2 File.
Characteristics of studies included in the current review
The 41 CUAs included were published 2002–2013 [14–54]. One study was based on empiric
cost and effectiveness data from a randomised controlled trial (RCT) [19], two on observation-
al data [16,37] while the remaining 38 studies used a modelling approach with multiple data
sources [14,15,17,18,20–36,38–54]. In 33 of the 38 modelling studies effectiveness estimates
were derived from one or more RCTs, while five modelling studies applied effectiveness ob-
tained from national registers. A summary of the characteristics of the CUAs included is
shown in Table 1.
Cost-effectiveness of biologics in patients with early RA and naïve to
cDMARDs
The cost-effectiveness of biologics for patients with early RA and naïve to cDMARDs were ana-
lysed in seven studies (Table 2). Four studies performed a comparison between biologics and
cDMARDs [14,21,28,38]. The ICERs of TNFi in comparison to cDMARDs ranged from 39,000
to 1 273,000 €/QALY when only direct costs were considered (Table 2). IFX was associated
with the highest ICERs ranging from 422,000 to 1 273,000 €/QALY while ICERs for ETN and
ADA as a monotherapy were below 100,000 €/QALY. As a combination therapy with MTX,
ICERs for ETN and ADA were substantially higher. If both direct and indirect costs were con-
sidered, ICERs for biologics were slightly more favourable.
Three out of the seven studies examined the cost-effectiveness of different treatment strate-
gies for early RA including TNFi in all treatment options, with only its time of usage in a treat-
ment sequence being altered [19,27,30]. Two studies found a late introduction of TNFi to be a
dominant strategy compared to initiation of the treatment with TNFi. Meanwhile van den
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Hout and colleagues found the ICER for TNFi as a first-line treatment option to be 215,000
€/QALY compared to its later introduction (Table 2).
Cost-effectiveness of biologics among patients with an inadequate
response to cDMARD
There were 21 studies comparing the biologics and cDMARDs in patients with an insufficient
response to cDMARDs (Table 3). When only direct costs were considered ICERs for IFX, ADA
and ETN were 12,000–282,000; 44,000–274,000 and 40,000–708,000, respectively. ABT and
TOC were associated with narrower ranges of ICERs (42,000 to 47,000 and 19,000 to 21,000,
respectively). ICERs below 35,000 €/QALY were found in three studies [20,29,51] and below
Fig 1. Flow chart of the study selection process.
doi:10.1371/journal.pone.0119683.g001
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50,000 €/QALY in ten studies [15,17,28,39,41,49,52]. The quality scores of the studies were not
associated with the magnitude of ICER values. Adequate comparator was applied in nine of 21
CUAs [15,23,28,29,32,35,36,46,50]. These studies provided higher ICERs compared to other
studies: only one CUAs with an adequate comparison treatment provided ICERs below 35,000
€/QALY for biologics when considering only direct costs [29].
Six studies performed comparisons between different biologics used in patients with an in-
adequate response to cDMARDs [20,24,28,32,33,50]. The results of these studies were contra-
dictory. Two studies [20,24] found ETN to be dominant over IFX and ADA, while three of the
other studies[28,32,50] reported ICERs ranging from 23,000 to 109,000 €/QALY for ETN
when only direct costs were included (Table 4). Two studies comparing TOC and ETN found
TOC to be the dominant strategy. None of these CUAs included indirect costs.
Table 4. Comparison of biologics in patients with an insufﬁcient response to cDMARD.




Source of research funding
IFX ETN Nguyen et al. 2012 [24] ETN dominates - One of the authors was
funded by UCB Pharma
CER Nguyen et al. 2012 [24] CER dominates - One of the authors was
funded by UCB Pharma
ADA GOL Nguyen et al. 2012 [24] ADA dominates - One of the authors was
funded by UCB Pharma
ETN Nguyen et al. 2012 [24] ETN dominates - One of the authors was
funded by UCB Pharma
IFX Chen et al. 2006 [28] 4,983—IFX is cost saving
(ADA➔ cDMARDs)
- NICE (UK)
IFX Chen et al. 2006 [28] ADA dominates (cDMARDs➔
ADA)
- NICE (UK)
ETN IFX Barton et al. 2004 [50] 68,373 42,760–88,266 NICE (UK)
IFX Jobanputra et al. 2002
[32]
109,297 (ETN➔ cDMARDs) 51,908–231,484 (ETN➔ cDMARDs) NICE (UK)
IFX Jobanputra et al. 2002
[32]
101,714 (cDMARDs➔ETN) 30,597–180,270 (cDMARDs➔ ETN) NICE (UK)
IFX Chen et al. 2006 [28] 38,541–47,884 (ETN➔
cDMARDs)
- NICE (UK)
IFX Chen et al. 2006 [28] 23,553 (cDMARDs➔ ETN) - NICE (UK)
ADA Soini et al. 2012 [20] ETN dominates - Roche
ADA Chen et al. 2006 [28] 35,621–61,315 (ETN➔
cDMARDs)
- NICE (UK)
ADA Chen et al. 2006 [28] 22,579–30,755 (cDMARDs➔
ETN)
- NICE (UK)
GOL ETN Nguyen et al. 2012 [24] ETN dominates - One of the authors was
funded by UCB Pharma
CER Nguyen et al. 2012 [24] CER dominates - One of the authors was
funded by UCB Pharma
CER ETN Nguyen et al. 2012 [24] 1 756,213 - One of the authors was
funded by UCB Pharma
TOC ETN Diamantopoulos et al.
2012 [33]
TOC dominates TOC dominates—19,187 Roche
ETN Soini et al. 2012 [20] TOC dominates—6,673 - Roche
➔ = switch to next treatment in case of an inadequate response, ADA = adalimumab, CER = certolizumab pegol, ETN = etanercept, GOL = golimumab,
ICER = Incremental cost-effectiveness ratio, IFX = inﬂiximab, NICE = National Institute for Health and Care Excellence, QALY = quality-adjusted life year,
TOC = tocilizumab
doi:10.1371/journal.pone.0119683.t004
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Cost-effectiveness of biologics among patients with an inadequate
response to at least one TNF inhibitor
Eight CUAs compared biologics and cDMARDs in patients who had had an insufficient re-
sponse to at least one TNFi [22,25,31,34,42,43,53,54]. RTX was associated with the lowest
ICERs ranging from 26,000 to 48,000 €/QALY (Table 5). Three of four studies evaluating RTX
provided ICERs below 35,000 €/QALY and none of the studies reported ICERs more than
50,000 €/QALY. ANA was associated with the highest ICERs with a range of 234,000–1
347,000 €/QALY. ICERs for the other agents ranged from 41,000 to 143,000 €/QALY. Inade-
quate comparator (MTX) was applied in three studies [34,42,43], and one study [25] did not
specify the comparator cDMARDs. However, the ICERs of these studies did not differ from
those of the other studies. Results of the four studies comparing one biologic to another
[18,31,34,53] indicated RTX as the most cost-effective biologic among patients with an insuffi-
cient response to a TNFi (Table 6).
Other studies
Three studies did not specify patients’ previous treatments, and therefore were not included in
the subgroups described above [37,40,47]. Farahani et al. estimated ICER for ETN in compari-
son to cDMARDs to be 71,000 €/QALY while applying the efficacy estimates based on a RCT
and 150,000 €/QALY when effectiveness estimates from an observational study were used [37].
Chiou et al. and Wailoo et al. performed comparisons of different biologics [40,47]. Both stud-
ies reported ETN to be dominant over IFX. Chiou et al. also found ETN to dominate ADA
while Wailoo et al. estimated ICER of 95,000 €/QALY for ETN in comparison to ADA.
Quality of the included studies
The average quality scores of the 41 studies included in the present review were 25.7 out of 35
(range 17 to 31) and 32.3 out of 57 (range 16 to 46) when evaluated using BMJ checklist and
Philips’ list, respectively (Table 7). The corresponding average percentages of the applicable
items fulfilled were 81 (range 57 to 100) and 62 (range 31 to 90) for BMJ check list and Philips’
list, respectively. The most frequent quality issues were the incomplete reporting of the data
sources, inappropriate comparator treatments, defects in the sensitivity analysis and the lack of
quality assessment of data used.
Discussion
We performed a systematic literature review of cost-effectiveness of biologics used for the treat-
ment of RA. After the literature search and the selection process of the initially identified re-
ports, 41 original articles were included in the current review. While considering only direct
costs, the ICERs of the TNFis ranged from 39,000 to 1 273,000 €/ QALY in comparison to
cDMARD in patients naïve to cDMARDs. Among patients with an inadequate response to
cDMARDs, biologics were associated with ICERs ranging from 12,000 to 708,000 €/QALY. In
this setting, none of the biologics appeared to be more cost-effective than any of the others.
ICERs for the second line biologics ranged from 26,000 to 1 347,000 €/QALY in comparison to
cDMARDs among patients with an inadequate response to TNFi. In this patient subgroup
RTX was the most and ANA the least cost-effective biologic. The quality assessment revealed
several problems, namely insufficient reporting of data sources and problematic methodologi-
cal details, which possibly reduce the validity of the results.
When assessing whether biologics are cost-effective or not, it should be known what the
willingness to pay for an additional QALY is. There is no widely accepted WTP threshold value
The Cost-Effectiveness of Biologics for RA: A Systematic Review
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for ICER although the National Institute for Health and Care Excellence (NICE) has published
a threshold of 20,000–30,000 £/QALY (~24,000–35,000 €/QALY) in United Kingdom [55].
Based on this statement by NICE we used the WTP threshold of 35,000 €/QALY. With this
threshold biologics are not cost-effective in cDMARD naïve patients. However, also much
Table 5. Cost-effectiveness of biologics in comparison with cDMARD among patients with an insufﬁcient response to at least one TNF inhibitor.






Source of research funding
RTX Yuan et al. 2010
[42]
47,931 - 57,370–96,012 BMS
Kielhorn et al.
2008 [31]
28,594 - 9,758–67,321 Roche
Brodszky et al.
2010 [34]




34,269 - 24,929–52,929 Roche
Malottki et al.
2011 [53]
30,021 - 16,220–65,448 NICE (UK)
IFX Hallinen et al.
2010 [54]
40,923 - 36,174–48,483 Roche
Malottki et al.
2011 [53]
51,362 - 40,976–98,029 NICE (UK)
ADA Hallinen et al.
2010 [54]
57,713 - 48,963–68,930 Roche
Malottki et al.
2011 [53]
48,801 - 39,980–87,216 NICE (UK)
ETN Hallinen et al.
2010 [54]
57,068 - 48,294–68,285 Roche
Malottki et al.
2011 [53]
55,346 - 44,248–108,558 NICE (UK)
Lekander et al.
2013 [25]
- 74,743 (ETN+cDMARD) 47,164–113,453 (ETN+DMARD) Wyeth (now Pﬁzer)
Lekander et al.
2013 [25]
- 88,861 (ETN) 53,769–175,126 (ETN) Wyeth (now Pﬁzer)
ABT Hallinen et al.
2010 [54]
75,910 - 65,232–90,234 Roche
Malottki et al.
2011 [53]
54,635 - 45,671–90,062 NICE (UK)
Vera-Llonch et al.
2008b [43]
45,275–49,802 - 40,211–79,438 Not stated, One of authors was
an employee of BMS
Yuan et al. 2010
[42]
41,207 - 49,912–81,509 BMS




- 100,378–671,413 NICE (UK)




- 82,533–216,370 NICE (UK)
TNFi Lekander et al.
2013 [25]





143,745 (TNFi) 126,813 (TNFi) 71,022–328,903 (TNFi) Wyeth (now Pﬁzer)
➔ = switch to next treatment in case of an inadequate response, ABT = abatacept, ADA = adalimumab, ANA = Anakinra, BMS = Bristol-Myers Squibb,
cDMARD = conventional disease-modifying antirheumatic drugs, ETN = etanercept, ICER = Incremental cost-effectiveness ratio, IFX = inﬂiximab, NICE =
National Institute for Health and Care Excellence, QALY = quality-adjusted life year, RTX = rituximab, TNFi = TNF inhibitor
doi:10.1371/journal.pone.0119683.t005
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higher WTP thresholds have been proposed and applied in the literature, but even with the
100,000 €/QALY threshold biologics do not seem to be cost-effective in this patient subgroup.
Slightly more preferable ICERs for ADA and ETN monotherapies do not count either: TNFi
monotherapy has later been found less effective than its combination with MTX and therefore,
biologics as monotherapies are not currently recommended [3,5]. In patients who have an in-
sufficient response to cDMARDs, biologics are not cost-effective with the 35,000 €/QALY
threshold, and with the higher thresholds of 50,000–100,000 €/QALY the evidence of their
cost-effective is conflicting. It should be noted that ADA, ETN and IFX, which have been for
the longest time on the market, have been assessed in several studies and are consequently asso-
ciated with a wide range of different ICERs. Meanwhile the narrower ranges of ICER values for
ABT and TOC probably reflect the lower number of studies rather than more consistent per-
formance of these agents. Health technology assessment reports provided by independent or-
ganisations such as NICE tend to provide higher ICERs than CUAs funded by pharmaceutical
companies, due to different premises of the studies. Such publicly funded and in this respect in-
dependent reports are not yet available for the newer agents such as TOC, which also may at
Table 6. Comparison of biologics among patients with an insufﬁcient response to at least one TNF inhibitor.








RTX Another TNFi Brodszky et al.
2010 [34]
RTX dominates RTX dominates - Center for Public Affairs
Studies Foundation and
Roche
2.TNFi➔ 3.TNFi Lindgren et al.
2009 [45]
RTX dominant RTX dominant RTX dominates—41,044 Roche




27,776 17,634 8,050–54,441 Roche




22,581 - - Roche
IFX RTX Malottki et al.
2011 [53]
RTX dominates - 5,833—RTX dominates NICE (UK)
ADA RTX Malottki et al.
2011 [53]
RTX dominates - 612—RTX dominates NICE (UK)
ETN Malottki et al.
2011 [53]
ADA dominates - ADA dominates-103,578 NICE (UK)
IFX Malottki et al.
2011 [53]
ADA dominates - 27,033–40,834 NICE (UK)
ETN RTX Malottki et al.
2011 [53]
RTX dominates - RTX dominates NICE (UK)
IFX Malottki et al.
2011 [53]
649,782 - 55,915—IFX dominates NICE (UK)
ABT RTX Malottki et al.
2011 [53]
185,815 - 73,273–1 225,153 NICE (UK)
ADA Malottki et al.
2011 [53]
66,017 - 57,053–119,656 NICE (UK)
ETN Malottki et al.
2011 [53]
53,781 - 47,663–71,992 NICE (UK)
IFX Malottki et al.
2011 [53]
59,329 - 52,500–81,952 NICE (UK)
➔ = switch to next treatment in case of an inadequate response, ABT = abatacept, ADA = adalimumab, ETN = etanercept, ICER = Incremental cost-
effectiveness ratio, IFX = inﬂiximab, NICE = National Institute for Health and Care Excellence, QALY = quality-adjusted life year, RTX = rituximab, TNFi =
TNF inhibitor
doi:10.1371/journal.pone.0119683.t006
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least in part explain more favourable ICERs. Among the patients with an inadequate response
to one TNFi, RTX appears cost-effective with the threshold of 35,000 €/QALY. With the higher
thresholds also other TNFis and ABT might be cost effective. These findings are consistent
with previous systematic reviews on the current topic [8–10].
We performed this review following current recommendations for systematic literature re-
view of economic evaluations [11]. Standardized methodology is a certain guarantee for the
quality and reliability of the current work. Source studies were restricted to CUAs, instead of all
CEAs, because QALY as a single measure of the effectiveness enables more accurate comparison
of the results. A further aim was to enhance the comparability of the studies by classifying them
by previous treatments and comparator treatments. Such a classification seems almost to be nec-
essary because the patient history is a key factor while assessing the external validity and trying
to generalize the results and because the comparator treatment has a great impact on ICERs.
The importance of adequate comparator has been previously raised by Tsao and colleagues
in their systematic review examining the cost-effectiveness of biologics in comparison to
cDMARDs [9]. MTX was the most frequent comparator in the studies included in the current
systematic review. MTX is the drug of choice in cDMARD naïve patient population [3]. On the
other hand, in patients with MTX monotherapy treatment failure this drug does not represent
an adequate treatment option. Instead patients should be treated with other cDMARDs or a
combination of cDMARDs they have not received before. In the current study ICERs were as-
sessed using comparator treatments and it seems that CUAs applying adequate comparators
may provide rather high ICERs. However, in spite of the general acceptance of MTX as an an-
chor drug in RA, there is a lack of consensus on the optimal cDMARDs sequence, which poses
a problem for CUAs.
It should be noticed that in spite of stratification of patients to subgroups, methodological
differences make a comparison of different CUAs difficult. Heterogeneity in time horizons, dis-
count rates, and perspectives were observed, all possibly inducing differences between the stud-
ies. For example, it is likely that a CUA with a longer time horizon produces more favourable
ICERs compared to ones with shorter time horizons [17,36,43]. While biologics are expensive,
they might induce future savings through decreased productivity losses and the lesser need for
surgery and inpatient care. A discount rate depreciates the future costs and benefits of the treat-
ment consequently reducing their impact on ICER.
Analyses counting only direct costs give an incomplete view of the pros and cons of different
treatments, while various methods used to estimate indirect costs remain controversial. In the
current study ICERs based only on direct costs and ICERs based on the inclusion of both direct
and indirect costs are provided if they were reported in the original source publication. It is
likely that biologics decrease productivity costs because they improve the health status of the
patients [5,6]. However, the age and employment status of treated population and the overall
labour costs have a major impact on indirect costs, introducing heterogeneity in the ICERs. For
example, in China where labour costs are low, Wu et al. reported only small differences be-
tween ICERs including direct or both direct and indirect costs, while in Sweden much larger
differences were observed [25,29,36,38,52]. The method used for the evaluation of productivity
costs generate further variation in ICERs when also indirect costs are considered: Van den
Hout et al. reported ICERs of 147,000€/QALY and 25,000€/QALY for early IFX treatment
using friction cost and human capital methods, respectively [19]. For these reasons it is more
transparent not to use ICERs with indirect costs when results of different studies are to be com-
pared. Accordingly, conclusions in the current review are based on ICERs including only direct
costs. Health service and other costs are always also related to national economy, health policy
and price level and thus ICERs cannot directly be generalized when analysing results from
different countries.
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Different methodologies used for the QALYmeasures have effect on ICERs. In most studies,
the utility scores of the multiattribute utility (MAU) instruments (e.g. EQ-5D) were derived
from the Health assessment questionnaire (HAQ) or some other disease specific measures. This
is necessary due to the fact that the MAU instruments have been applied in few RCTs, while dis-
ease specific measures such as HAQ have been commonly used in RCTs. Application of different
formulas for conversions introduce a further source of heterogeneity in ICERs estimates [44].
Different MAU instruments without any conversions produce different utility scores and hence,
different ICERs [19]. Standardization of MAU instruments and a validated standard conversion
method for missing utility measures would enable better comparison between different CUAs.
In most studies the effectiveness estimates were based on one or several RCTs, representing
rather estimates for efficacy. While RCTs are the key source for the efficacy evidence in medi-
cines, they have some weaknesses if applied as source of effectiveness estimates in economic
evaluations. Firstly, the results of RCTs are generally better than in the clinical practice because
patients are carefully selected and adherence is usually better to RCTs than to regular clinical
practices. Consequently, ICERs based on efficacy estimates from RCTs tend to be much lower
than those based on observational data as shown by Farahani et al. [37]. Secondly, an objective
of RCTs is usually to explore an efficacy of a single treatment in comparisons to placebo (or
MTX in case of several RCTs studying biologics for RA), rather than compare complex treat-
ment strategies. In contrast, CUAs aim to compare active treatments reflecting real life prac-
tices, and therefore indirect comparisons of RCTs are often necessary. However, some CUAs
which used effectiveness estimates obtained from several RCTs reported indirect comparisons
inadequately. This, restricted clinical evidence and therefore somewhat inconsistent results
from CUAs explain that the ranking of biologics remains unclear among patients having inade-
quate response for cDMARDs [6]. To advance CUAs even further, indirect comparisons could
in the future be performed and reported according to current guidelines [56].
The quality of economic evaluations was assessed using two different checklists, and was
found to be suboptimal. The quality scores according the BMJ checklist were rather high while
Philips’ checklist provided less favorable estimates of the study qualities. The reason for this dis-
crepancy is probably the extensiveness of the Philips’ checklist, which covers several topics not
considered in the BMJ checklist. An interesting finding was that quality scores of the studies were
not associated with the magnitude of ICER. This is perhaps based on the nature of checklists: a
single and simple modeling assumption may have a great impact on ICERs even if its effect on
quality scores remains minor. In addition to the quality assessment of the individual studies, we
assessed the bias across the CUAs. Only a few of the older conference abstracts identified through
the literature search have been published later as a full article, indicating a reporting bias. Howev-
er, conference abstracts were not included in the current systematic literature review due to in-
complete information and problems with quality assessment that may bias their results. The risk
of a language bias seems minor based on the small number of non-English papers excluded.
Conclusions
With the WTP threshold of 35,000 €/QALY, biologics do not seem to be cost-effective among
cDMARD naïve patients or cDMARD resistant patients. Among patients with an inadequate
response to TNFi(s), RTX seems to be cost-effective. With thresholds of 50,000–100,000
€/QALY biologics might be cost-effective among cDMARD resistant patients.
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